Home/Filings/4/0001209191-23-056267
4//SEC Filing

Crockett Thomas Andrew 4

Accession 0001209191-23-056267

CIK 0001348911other

Filed

Nov 20, 7:00 PM ET

Accepted

Nov 21, 4:30 PM ET

Size

15.0 KB

Accession

0001209191-23-056267

Insider Transaction Report

Form 4
Period: 2023-11-17
Crockett Thomas Andrew
DirectorPresident and CEO
Transactions
  • Exercise/Conversion

    Common Stock

    2023-11-17+33,583172,339 total
  • Exercise/Conversion

    Restricted Stock Unit

    2023-11-176,94555,556 total
    Common Stock (6,945 underlying)
  • Exercise/Conversion

    Performance Stock Unit

    2023-11-1720,8330 total
    Common Stock (20,833 underlying)
  • Sale

    Common Stock

    2023-11-20$8.23/sh14,807$121,851157,532 total
  • Exercise/Conversion

    Restricted Stock Unit

    2023-11-175,80558,050 total
    Common Stock (5,805 underlying)
Footnotes (6)
  • [F1]Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.
  • [F2]The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs and performance stock units ("PSUs"). The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
  • [F3]1/12th of the total number of shares subject to the RSU shall vest on each quarterly anniversary of the Vesting Commencement Date commencing on November 17, 2022, for a period of three years, subject to continued service through each vesting date.
  • [F4]1/16th of the total RSUs subject to the Award shall vest on each quarterly anniversary of the Vesting Commencement Date thereafter, subject to continued service through each vesting date.
  • [F5]Each PSU represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.
  • [F6]Shares earned upon the vesting of a percentage of the PSUs granted to the Reporting Person on June 8, 2023. Each PSU represents a contingent right to receive one share of Issuer common stock upon the Issuer's achievement of Performance Data and Enrollment Metrics goals ("Performance Metrics"). 1/4th of the total number of shares subject to the PSU shall vest on each quarterly anniversary of the Vesting Commencement Date of November 17, 2023, upon Performance Metrics achieved, subject to continued service through each vesting date.

Issuer

KalVista Pharmaceuticals, Inc.

CIK 0001348911

Entity typeother

Related Parties

1
  • filerCIK 0001690920

Filing Metadata

Form type
4
Filed
Nov 20, 7:00 PM ET
Accepted
Nov 21, 4:30 PM ET
Size
15.0 KB